Blood neoplasia Journal

Overview

publication venue for

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.. 2. 2025
Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis.. 2. 2025
A feedforward loop between ACLY and MYC supports T-ALL progression in vivo.. 2. 2025
Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma.. 1. 2024

Identity

ISO Abbreviation

Blood Neoplasia

Linking ISSN

2950-3280

Electronic International Standard Serial Number (EISSN)

2950-3280